Skip to main content

Advertisement

SpringerLink
Log in

Systemic lupus erythematosus vasculitis: A current therapeutic overview

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

The development of systemic lupus erythematosus (SLE) vasculitis is of prognostic value. The earlier the vasculitis is treated, the better the prognosis for SLE. Cutaneous vasculitis is common in SLE, whereas visceral vasculitis is rare. Skin SLE vasculitis is successfully treated with antimalarials, but its discontinuation may result in an SLE flare even among patients in remission. When visceral SLE vasculitis is encountered, or when a disease state is perceived to be life-threatening, a more aggressive therapy is warranted. A combination of medications, plasmapheresis, and intravenous immunoglobulin treatment, along with high-dose steroids and cytotoxic drugs, are typically employed in the treatment of severe SLE vasculitis. Finally, patients with SLE vasculitis may benefit from a number of autoimmune disease therapies currently under investigation, such as switching cytokine responses from Th1 to Th2, and the manipulation of toll-like receptors, chemokines, and FcR receptors. Specific B-cell therapies (eg, anti-Blys, B-cell depletion) may also emerge as potential treatments for SLE vasculitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Estes D, Christian CL: The natural history of systemic lupus erythematosus by prospective analysis. Medicine 1971, 50:85–95.

    Article  PubMed  CAS  Google Scholar 

  2. Grigor R, Edmonds J, Lewkonia R, et al.: Systemic lupus erythematosus. A prospective analysis. Ann Rheum Dis 1978, 37:121–128.

    Article  PubMed  CAS  Google Scholar 

  3. Rothfield N, Marino C: Studies of repeat skin biopsies of non-lesional skin in patients with systemic lupus erythematosus. Arthritis Rheum 1982, 25:624–630.

    Article  PubMed  CAS  Google Scholar 

  4. Hochberg MC: Systemic lupus erythematosus. Rheum Dis Clin North Am 1990, 16:617–639.

    PubMed  CAS  Google Scholar 

  5. Drenkard C, Villa AR, Reyes E, et al.: Vasculitis in systemic lupus erythematosus. Lupus 1997, 6:235–242.

    Article  PubMed  CAS  Google Scholar 

  6. Flores-Suarez LF, Alacron-Segovia D: Vasculitis in connective tissue disease. Curr Rheumatol Rep 2000, 2:396–401.

    Article  Google Scholar 

  7. Gladman DD, Urowitz MD: Systemic lupus erythematosus, clinical features. In Rheumatology. Edited by Kippel JH, Dieppe PA. London: Mosby; 1998:1–18.

    Google Scholar 

  8. Gladman DD, Hirani N, Ibanez D, Urowitz MB: Clinically active serologically quiescent systemic lupus erythematosus. J Rheumatol 2003, 30:1960–1962.

    PubMed  Google Scholar 

  9. Bresnihan B: Outcome and survival in systemic lupus erythematosus. Ann Rheum Dis 1989, 48:443–445.

    Article  PubMed  CAS  Google Scholar 

  10. Molina JF: Systemic lupus erythematosus in males. A study of 107 Latin American patients. Medicine 1996, 75:124–130.

    Article  PubMed  CAS  Google Scholar 

  11. Cardinali C, Caproni M, Bernacchi E, et al.: The spectrum of cutaneous manifestations in lupus erythematosus. The Italian experience. Lupus 2000, 9:417–423.

    Article  PubMed  CAS  Google Scholar 

  12. McCauliffe DP: Cutaneous lupus erythematosus. Semin Cutan Med Surg 2001, 20:14–26. A very good review on the wide spectrum of cutaneous manifestations in SLE.

    Article  PubMed  CAS  Google Scholar 

  13. Yell JA, Mbuagbaw J, Burge SM: Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol 1996, 135:355–362.

    Article  PubMed  CAS  Google Scholar 

  14. Asherson RA, Cruz DD, Stephens CJM, et al.: Urticarial vasculitis in connective tissue diseases clinic: patterns, presentations and treatment. Semin Arthritis Rheum 1991, 20:285–296.

    Article  PubMed  CAS  Google Scholar 

  15. Ng PP, Tan SH, Tan T: Lupus erythematosus panniculitis: a clinicopathologic study. Int J Dermatol 2002, 41:488–490.

    Article  PubMed  Google Scholar 

  16. Moore PM: Vasculitis of the central nervous system. Curr Rheumatol Rep 2000, 2:376–382.

    Article  PubMed  CAS  Google Scholar 

  17. Ruggieri AP: Neuropsychiatric lupus: nomenclature, classification, criteria, and other confusional states. Arthritis Rheum 2001, 45:406–409.

    Article  PubMed  CAS  Google Scholar 

  18. Omdal R: Some controversies of neuropsychiatric systemic lupus erythematosus. Scand J Rheumatol 2002, 31:192–197.

    Article  PubMed  Google Scholar 

  19. Johnson RT, Richardson EP: The neurological manifestations of systemic lupus erythematosus: a clinicalpathological study of 24 cases and review of literature. Medicine (Baltimore) 1968, 47:337–369.

    Article  CAS  Google Scholar 

  20. Lie JT: Vasculopathy of the antiphospholipid syndrome revisited: thrombosis is the culprit and vasculitis is consort. Lupus 1996, 5:368–371.

    PubMed  CAS  Google Scholar 

  21. Mawrin C, Brunn A, Rocken C, Schroder JM: Peripheral neuropathy in systemic lupus erythematosus: pathomorphological features and distribution pattern of matrix metalloproteinases. Acta Neuropathol (Berl) 2003, 105:365–372.

    CAS  Google Scholar 

  22. Specks U: Diffuse alveolar hemorrhage syndromes. Curr Opin Rheumatol 2001, 13:12–17.

    Article  PubMed  CAS  Google Scholar 

  23. Santos-Ocampo AS, Mandell BF, Fessler BJ: Alveolar hemorrhage in systemic lupus erythematosus: presentation and management. Chest 2000, 118:1083–1090.

    Article  PubMed  CAS  Google Scholar 

  24. Sultan SM, Ioannou Y, Isenberg DA: A review of gastrointestinal manifestations of systemic lupus erythematosus. Rheumatology (Oxford) 1999, 38:917–932.

    Article  CAS  Google Scholar 

  25. Geboes K, Dalle I: Vasculitis and gastrointestinal tract. Acta Gastroenterol Belg 2000, 65:204–212.

    Google Scholar 

  26. Caso V, Paciaroni M, Parnetti L, et al.: Stroke related to carotid artery dissection in a young patient with Takayasu arteritis, SLE and APS. Cerebrovasc Dis 2002, 13:67–69.

    Article  PubMed  CAS  Google Scholar 

  27. Wilson WA, Gharavi EA, Koike T, et al.: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Report of an international workshop. Arthritis Rheum 1999, 42:1309–1311.

    Article  PubMed  CAS  Google Scholar 

  28. Navarrete MG, Brey RL, Levine SR: Cerebral disease in the antiphospholipid syndrome. In Hughes Syndrome: Antiphospholipid Syndrome. Edited by Khamashta MA. London: Springer-Verlag; 2000:43–58. A good review and summary of literature on the differentiation between APS and vasculitis in CNS SLE.

    Google Scholar 

  29. Sailer M, Burchert W, Ehrenheim C, et al.: Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus. J Neurol 1997, 244:186–193.

    Article  PubMed  CAS  Google Scholar 

  30. Cuellar MC, Espinoza LR: Laboratory testing in the evaluation and diagnosis of vasculitis. Curr Rheumatol Rep 2000, 2:417–422. A comprehensive presentation on the wide range of laboratory analyses that are used for establishing SLE activity and vasculitis.

    Article  PubMed  CAS  Google Scholar 

  31. Beaufils M, Kouki F, Mignon F, et al.: Clinical significance of anti-Sm antibodies in systemic lupus erythematosus. Am J Med 1983; 74:201–205.

    Article  PubMed  CAS  Google Scholar 

  32. Renaudineau Y, Dugue C, Dueymes M, et al.: Antiendothelial cell antibodies in systemic lupus erythematosus. Autoimmun Rev 2002, 1:365–372.

    Article  PubMed  CAS  Google Scholar 

  33. Sen D, Isenberg DA: Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus 2003, 12:651–658.

    Article  PubMed  CAS  Google Scholar 

  34. Wallace DJ: Antimalarials: the real advance in lupus. Lupus 2001, 10:385–387.

    Article  PubMed  CAS  Google Scholar 

  35. Molad Y, Gorshtein A, Wysenbeek AJ, et al.: Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 2002, 11:356–361.

    Article  PubMed  CAS  Google Scholar 

  36. Toubi E, Rosner I, Rosenbaum M, et al.: The benefit of combined hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus 2000, 9:92–95.

    Article  PubMed  CAS  Google Scholar 

  37. A randomized study of the effect of with drawing hydroxychloroguine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group [no authors listed]. N Engl J Med 1991, 324:150–154.

  38. Al-Herz A, Schulzer M, Esdaile JM: Survey of antimalarial use in lupus pregnancy and lactation. J Rheumatol 2002, 29:700–706. This study deals with the safety of using HCQ during pregnancy in patients with SLE.

    PubMed  Google Scholar 

  39. Karim MY, Ruiz-Irastorza G, Khamashta MA, et al.: Update on therapy-thalidomide in the treatment of lupus. Lupus 2001, 10:188–192.

    Article  PubMed  CAS  Google Scholar 

  40. Ossandon A, Cassara EA, Priori R, et al.: Thalidomide: focus on its employment in rheumatic diseases. Clin Exp Rheumatol 2002, 20:709–718.

    PubMed  CAS  Google Scholar 

  41. Wolf R: Dapsone: un-approval use or indications. Clin Dermatol 2000, 18:37–53.

    Article  PubMed  CAS  Google Scholar 

  42. Fabbri P, Cardinali C, Giomi B, et al.: Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol 2003, 4:449–465.

    Article  PubMed  Google Scholar 

  43. Badsha H, Edwards CJ. Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin Arthritis Rheum 2003, 32:370–377. This study questions the need for high-dose pulse therapy with corticosteroids, and suggests a lower beneficial dose that may cause a lower incidence of infections.

    Article  PubMed  CAS  Google Scholar 

  44. Levy Y, Sherer Y, Ahmed A, et al.: A study of 20 SLE patients with intravenous immunoglobulin: clinical and serological responses. Lupus 1999, 8:705–712.

    Article  PubMed  CAS  Google Scholar 

  45. Perez C, Guarch R, Rodrigo M, et al.: Successful treatment of leukocytoclastic vasculitis and pancytopenia secondary to systemic lupus erythematosus with intravenous immunoglobulin. Br J Dermatol 2002, 147:180–182.

    Article  PubMed  CAS  Google Scholar 

  46. Martin-Suarez I, D’Cruz D, Mansoor M, et al.: Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 1997, 56:481–487.

    Article  PubMed  CAS  Google Scholar 

  47. Houssiau FA, Vasconcelos C, D’Cruz D, et al.: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002, 46:2121–2131. Whereas a pulsing high dose of cyclophosphamide is associated with a high rate of side effects, lower intravenous pulses are suggested to be both safe and efficient.

    Article  PubMed  CAS  Google Scholar 

  48. Ioannou Y, Isenberg DA: Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge. Postgrad Med J 2002, 78:599–606.

    Article  PubMed  CAS  Google Scholar 

  49. Petri M: Immunosuppressive drug use in pregnancy. Autoimmunity 2003, 36:51–56. A good review on the safety of using immunosuppressive drugs during pregnancy.

    Article  PubMed  CAS  Google Scholar 

  50. Ruiz-Irastorza G, Khamashta MA, Hughes GR: Therapy of systemic lupus erythematosus: new agents and new evidence. Expert Opin Investig Drugs 2000, 9:1581–1593.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Immunology, Bnai-Zion Medical Center, P.O. Box 4940, 31048, Haifa, Israel

    Elias Toubi MD, Aharon Kessel MD, Ellen Bamberger MD & Theo Dov Golan MD

Authors
  1. Elias Toubi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aharon Kessel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ellen Bamberger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Theo Dov Golan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Toubi, E., Kessel, A., Bamberger, E. et al. Systemic lupus erythematosus vasculitis: A current therapeutic overview. Curr Treat Options Cardio Med 6, 87–97 (2004). https://doi.org/10.1007/s11936-004-0036-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-004-0036-1

Keywords

Search

Navigation